Tvardi Therapeutics, Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the development of innovative oncology therapies and addressing significant unmet medical needs. Utilizing its proprietary drug discovery platform, Tvardi focuses on small molecule therapies that target protein degradation pathways to improve treatment outcomes for cancer patients. The company’s lead candidate, TVB-2640, disrupts mechanisms that allow cancer cells to survive, underscoring its commitment to advancing novel therapeutic options. With a strong pipeline and an emphasis on scientific rigor, Tvardi is strategically poised to make a substantial impact on the evolving landscape of cancer treatment.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-29.35M |
| Operating Margin | 0.00% |
| Return on Equity | -237.80% |
| Return on Assets | -68.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.55 |
| Price-to-Book | 1.31 |
| Price-to-Sales (TTM) | 559.61 |
| EV/Revenue | 539.62 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $9.38M |
| Float | $5.67M |
| % Insiders | 34.64% |
| % Institutions | 28.93% |
Volatility is currently contracting
Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) and B cells Company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal (GI) diseases - subject to additional funding Company to host investor webcast today, July 7 th , at 8:30am ET HOUSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced Phase 1 results for TTI-109, its next-generation STAT3 inhibitor. TTI-109 is a phosphate prodrug of TTI-101 designed to improve delivery and tolerability while preserving the parent compound's mechanism of action.
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events: Jefferies Global Healthcare Conference Format: Fireside Chat and 1-on-1 MeetingsDate: Thursday, June 4, 2026Time: 8:10 AM ETLocation: New York, NY Raymond James BioPharma CEO Strategy Series Format: Fireside ChatDate: Friday, June 5, 2026Time: 10:00 AM ETRegistration Link: Here The webcasts of the Jefferies and Raymond James fireside chats will be accessible on the Tvardi Investors' website. A replay of the webcasts will be available for approximately 90 days following the conference.
Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) on track for 2H 2026 Cash runway expected to be sufficient to fund operations through clinical readouts and into Q4 2026 HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the first quarter ended March 31, 2026, and provided a business update. Recent Progress and Upcoming Catalysts: TTI-109 (Healthy Volunteer Study): Study ongoing with topline data anticipated in June 2026.
